-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Abbott Laboratories, Lowers Price Target to $115

Benzinga·04/17/2026 17:29:21
Listen to the news
Piper Sandler analyst Adam Maeder maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $135 to $115.